Anish Nikhanj

Anshi

Graig Suvannavejh

James Molloy

Justin Zelin

Kelly Hsu

Leonid Timmasheev

Michael Schmidt

Paul Jeng

Pete Stavropoulos

Sean Lee

Yuan Zhi

- Verastem received approval for its novel drug combination (budametinib and defactinib) for low-grade serous ovarian cancer (LGSOC) **two months ahead of schedule** and reported **$2.1 million** in revenue in the **first six weeks** of launch.  **[1526119_tx_380190_0]** **[1526119_tx_380190_1]** 
- The company has expanded its distribution channels by adding **three specialty distributors** and securing GPO contracts, and is pursuing NCCN guideline inclusion for KRAS wild type LGSOC, with a review scheduled for **October**.  **[1526119_tx_380190_2]** 
- Verastem's KRAS G12D inhibitor has shown high response rates, including **83%** in frontline metastatic pancreatic cancer and **69%** in KRAS G12D lung cancer.  **[1526119_tx_380190_9]** 
- The company anticipates a gross-to-net of **15% to 20%** and is utilizing a **zero co-pay program** to support patient access, with patient retention expected to build an "annuity" due to long treatment durations (average **18 months** for KRAS mutant, **11 months** for wild type).  **[1526119_tx_380190_3]** **[1526119_tx_380190_5]**

Verastem Provides Update on LGSOC Drug Launch and Pipeline Progress

Verastem (VSTM)